Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MICROMET, INC. (MITI)
|
Add to portfolio |
|
|
|
| Price: |
$0.19
| | Metrics |
| OS: |
95.3
|
M
| |
-67
|
% ROE
|
| Market cap: |
$18.1
|
M
| |
-1548
|
% ROIC
|
|
Net cash:
|
$159
|
M
| |
$1.67
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($79.1)
|
M
| |
|
|
|
EBIT
|
($81.6)
|
M
| |
|
|
| EPS |
($90.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| Revenues | 21.9 | 28.7 | 21.0 | 27.3 | 18.4 | 27.6 | 25.7 | 16.7 |
| Revenue growth | -23.7% | 36.6% | -22.9% | 48.4% | -33.4% | 7.2% | 53.7% | -39.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 15.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 21.9 | 28.7 | 21.0 | 11.8 | 18.4 | 27.6 | 25.7 | 16.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 43.2% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 77.4 | 49.4 | 53.4 | | | | | |
| General and administrative | 26.1 | 21.4 | 17.0 | 15.5 | 14.4 | 12.0 | 6.9 | 5.6 |
| EBIT | -81.6 | -42.1 | -49.4 | -26.1 | -25.2 | -12.7 | -9.7 | -21.9 |
| EBIT margin | -372.1% | -146.3% | -234.7% | -95.5% | -137.3% | -46.0% | -37.8% | -131.0% |
| Pre-tax income | -74.2 | -50.1 | -56.1 | -33.2 | -20.1 | -34.0 | -14.3 | -25.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -74.2 | -50.1 | -56.1 | -33.2 | -20.1 | -34.0 | -14.3 | -25.1 |
| Net margin | -338.4% | -174.4% | -266.5% | -121.8% | -109.5% | -123.2% | -55.5% | -149.7% |
| |
| Diluted EPS | ($0.81) | ($0.63) | ($0.96) | ($767.39) | ($0.55) | ($1.29) | ($2.77) | ($16.65) |
| Shares outstanding (diluted) | 91.7 | 79.7 | 58.6 | 0.0 | 36.4 | 26.4 | 5.1 | 1.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|